Good
Partially Aligned
Patient Risk:
Low
Summary
Most adverse-effect and warning-related claims are consistent with the provided COSENTYX label excerpts (infections, hypersensitivity including anaphylaxis, and need for caution/monitoring). However, several specificity elements (e.g., exact infection types like bronchitis/pneumonia and statements about FDA warning language) are not explicitly supported by the excerpts, and one patient-caution statement is broader than the label text provided.
Category Scores
Accurate Statements
Cosentyx can cause injection site reactions.
Not supported by the provided excerpts (no injection-site reaction text included).
Cosentyx can cause headache.
Not supported by the provided excerpts (no headache text included).
Cosentyx can cause fatigue.
Not supported by the provided excerpts (no fatigue text included).
Cosentyx can cause myalgia (muscle pain).
Not supported by the provided excerpts (no myalgia text included).
Cosentyx can cause arthritis.
Not supported by the provided excerpts (no arthritis adverse reaction text included).
Cosentyx can cause arthralgia (joint pain).
Not supported by the provided excerpts (no arthralgia adverse reaction text included).
Cosentyx can cause hypersensitivity reactions.
Supported: Section 5.2 Hypersensitivity Reactions (serious hypersensitivity including anaphylaxis, angioedema, urticaria).
Hypersensitivity reactions from Cosentyx may be life-threatening.
Partially supported: Section 5.2 describes serious hypersensitivity including anaphylaxis and states immediate discontinuation and appropriate therapy; explicit 'life-threatening' wording not present in the provided excerpt.
Cosentyx can cause infections.
Supported: Section 5.1 Infections (may increase risk; serious bacterial/viral/fungal opportunistic; some fatal infections reported).
Cosentyx can cause gastrointestinal problems.
Partially supported: Section 5.4 Inflammatory Bowel Disease (IBD exacerbations; monitor for signs/symptoms). Explicit 'gastrointestinal problems' not quoted.
Cosentyx can cause allergic reactions.
Supported: Section 5.2 Hypersensitivity Reactions (includes anaphylaxis, angioedema, urticaria).
Allergic reactions associated with Cosentyx can include anaphylaxis.
Supported: Section 5.2 (serious hypersensitivity including anaphylaxis). Also postmarketing includes anaphylaxis in Section 6.2.
Patients with a history of hypersensitivity reactions should exercise caution before taking Cosentyx.
Partially supported: Section 5.2 describes hypersensitivity reactions; Contraindications include previous serious hypersensitivity to secukinumab/excipients (Section 4). The provided caution language for 'history of hypersensitivity reactions' is not explicitly stated as 'exercise caution' in the excerpts, but the contraindication indicates contraindicated for prior serious hypersensitivity.
The FDA warns that Cosentyx may cause an increased risk of infections.
Supported in substance: Section 5.1 Infections (may increase risk of infections; serious/fatal infections have been reported).
The FDA warns that the increased risk of infections with Cosentyx can include tuberculosis.
Partially supported: Section 5.3 requires evaluation for active/latent TB and states avoid initiating in active TB; it supports TB risk evaluation/concern. The excerpt does not explicitly state 'increased risk of infections can include tuberculosis' as wording.
Unsupported Statements
Cosentyx can cause nasopharyngitis (inflammation of the nasal passages and sinuses).
No nasopharyngitis adverse reaction text is included in the provided label excerpts.
Cosentyx can cause injection site reactions.
No injection site reaction adverse reaction text is included in the provided label excerpts.
Cosentyx can cause headache.
No headache adverse reaction text is included in the provided label excerpts.
Cosentyx can cause fatigue.
No fatigue adverse reaction text is included in the provided label excerpts.
Cosentyx can cause myalgia (muscle pain).
No myalgia adverse reaction text is included in the provided label excerpts.
Cosentyx can cause arthritis.
No arthritis adverse reaction text is included in the provided label excerpts.
Cosentyx can cause arthralgia (joint pain).
No arthralgia adverse reaction text is included in the provided label excerpts.
Cosentyx can cause fatigue.
No fatigue adverse reaction text is included in the provided label excerpts.
Infections associated with Cosentyx can include bronchitis.
No bronchitis-specific infection example is included in the provided label excerpts.
Infections associated with Cosentyx can include pneumonia.
No pneumonia-specific infection example is included in the provided label excerpts.
Gastrointestinal problems from Cosentyx can include diarrhea.
No diarrhea-specific adverse reaction example is included in the provided label excerpts.
Gastrointestinal problems from Cosentyx can include stomach pain.
No stomach pain-specific adverse reaction example is included in the provided label excerpts.
The FDA warns that the increased risk of infections with Cosentyx can include tuberculosis.
The provided excerpts support TB evaluation/monitoring (active/latent TB, avoid active TB), but do not explicitly state tuberculosis as an 'included' infection type under the 'increased risk of infections' phrasing.
Contradictions
Important Omissions
If the AI response intended to communicate full hypersensitivity guidance, the label excerpts specify that prior serious hypersensitivity to secukinumab or excipients is a contraindication and that if anaphylaxis/other serious allergic reaction occurs, immediately discontinue and initiate appropriate therapy (and includes specific reactions: angioedema, urticaria).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The label excerpts broadly support infection risk and serious hypersensitivity (including anaphylaxis), but multiple specific symptom/infection-site examples are not supported by the provided excerpts; these are less likely to be directly unsafe but indicate possible over-specificity and potential misinforming of expected adverse events. No direct contradictions to the provided label excerpts were identified.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claimed adverse events and specific infection/GI manifestations (nasopharyngitis, injection site reactions, headache, fatigue, myalgia, arthritis, arthralgia, bronchitis, pneumonia, diarrhea, stomach pain) are not supported by the provided COSENTYX label excerpts; and one TB statement is over-specific relative to the excerpt wording.
Suggested Improvement
Limit adverse-event examples to those explicitly supported in the provided excerpts (e.g., infections broadly; hypersensitivity including anaphylaxis/angioedema/urticaria; TB evaluation/monitoring; IBD exacerbations) or provide the additional label sections/excerpts that list the more specific symptoms (e.g., diarrhea, pneumonia, nasopharyngitis).